InvestorsHub Logo
Followers 89
Posts 17579
Boards Moderated 0
Alias Born 09/06/2006

Re: flipper44 post# 315007

Wednesday, 10/07/2020 12:20:14 PM

Wednesday, October 07, 2020 12:20:14 PM

Post# of 709686
"weird" Why?

NVCR has been doing well. Growing revenue, plenty of cash.

The MRK collaboration has probably been one of the main drivers over the last several months. They have had their LUNAR combo trial in second line NSCLC, and a few little ISTs. But now they are looking at first line in KEYNOTE 36. I do not know the specifics, but the name alone tells you that MRK has an active interest.

They have been marching forward with their label expansion trials. The NSCLC brain mets trial alone is 5x larger than GBM.

They have been working on technology. Software that tunes the E&M to the patient. New transducers. Tweaking levels.

People around here have been talking about shorting NVCR for a few years.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News